Cargando…

Upper thigh skeletal muscle index predicts outcomes in liver transplant recipients

PURPOSE: The skeletal muscle index (SMI) at the L3 level is widely used to diagnose sarcopenia. The upper thigh (UT) also reflects changes in whole-body muscle mass, but no study has examined this using the UT to diagnose sarcopenia in liver transplantation (LT). This study aimed to determine an opt...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Manuel, Kim, Jong Man, Yang, Jaehun, Kwon, Jieun, Kim, Kyeong Deok, Jeong, Eun Sung, Rhu, Jinsoo, Choi, Gyu-Seong, Joh, Jae-Won, Lee, Suk-Koo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Surgical Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613820/
https://www.ncbi.nlm.nih.gov/pubmed/37908380
http://dx.doi.org/10.4174/astr.2023.105.4.219
Descripción
Sumario:PURPOSE: The skeletal muscle index (SMI) at the L3 level is widely used to diagnose sarcopenia. The upper thigh (UT) also reflects changes in whole-body muscle mass, but no study has examined this using the UT to diagnose sarcopenia in liver transplantation (LT). This study aimed to determine an optimal cut-off value for UT-SMI and investigate how sarcopenia diagnosed by UT-SMI correlates with outcomes in LT recipients. METHODS: In this retrospective study of 332 LT patients from 2018 to 2020, we investigated the association between sarcopenia diagnosed by UT-SMI and patient outcomes after LT. RESULTS: The cut-off values for UT-SMI were 38.3 cm(2)/m(2) for females (area under the curve [AUC], 0.927; P < 0.001) and 46.7 cm(2)/m(2) for males (AUC, 0.898; P < 0.001). The prevalence of sarcopenia diagnosed by UT-SMI was 33.4% in our cohort. Patient and graft survival rates in the UT-SMI sarcopenia group were significantly poorer than those in the UT-SMI non-sarcopenia group (P < 0.001 and P < 0.001). UT-SMI was an independent prognostic factor for patient survival (hazard ratio [HR], 2.182; 95% confidence interval [CI], 1.183–4.025; P = 0.012) and graft survival (HR, 2.227; 95% CI, 1.054–4704; P = 0.036) in our multivariable Cox analysis. CONCLUSION: We confirmed that sarcopenia diagnosed by UT-SMI is associated with outcomes in LT recipients. In addition, UT-SMI was identified as an independent prognostic factor for patient survival and graft survival. Therefore, UT-SMI could be a good option for CT-based evaluations of sarcopenia in LT recipients.